

## CLAIMS

1. Use of anifrolumab in the manufacture of a medicament for treating systemic lupus erythematosus (SLE) in a subject in need thereof, wherein a therapeutically effective amount of the medicament is to be administered to the subject, wherein the subject has an IL-10 plasma concentration lower than about 2 pg/ml at baseline, and wherein the medicament reduces SLE disease activity in the subject.
2. The use of claim 1, wherein the subject has an elevated type I IFN gene signature (IFNGS) at baseline compared to a healthy subject.
3. The use of claim 2, wherein an elevated IFNGS comprises at least four-fold increase in mRNA of at least four of IFI27, IFI44, IFI44L, IFI6, and RSAD2 in a sample from the subject and/or subjects, relative to a sample from a healthy subject.
4. The use of claim 2, wherein an elevated IFNGS comprises at least four-fold increase in mRNA of at least four of IFI27, IFI44, IFI44L, IFI6, and RSAD2 in a sample from the subject and/or subjects, relative to pooled samples from healthy patients.
5. The use of claim 2, wherein an elevated IFNGS comprises at least four-fold increase in mRNA of at least four of IFI27, IFI44, IFI44L, IFI6, and RSAD2 in a sample compared to the mRNA of one or more control genes in the sample.
6. The use of claim 5, wherein the one or more control genes are chosen from ACTB, GAPDH, and 18S rRNA.
7. The use of any preceding claim, wherein the IL-10 concentration in a plasma sample from the subject is measured.
8. The use of claim 7, wherein the IL-10 concentration is measured by immunoassay, optionally wherein the immunoassay is a Luminex or Simoa immunoassay.
9. The use of any preceding claim, wherein the medicament comprises 300 mg anifrolumab.
10. The use of claim 9, wherein the medicament is to be administered to the subject as an intravenous (IV) infusion.
11. The use of claim 10, wherein the medicament is to be administered the subject every 4 weeks.
12. The use of any one of claims 1 to 8, wherein the medicament comprises 120 mg anifrolumab.
13. The use of claim 12, wherein the medicament is to be administered subcutaneously.
14. The use of claim 13, wherein the medicament is to be administered to the subject every week.
15. The use of any of any preceding claim, wherein the subject has moderate to severe SLE.